{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:13:43Z","timestamp":1790082823111,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08928-y","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:04:37Z","timestamp":1788599077000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Microfluidic-based rapid generation of chimeric antigen receptor T cells improves low-multiplicity-of-infection transduction efficiency while preserving functional activity"],"prefix":"10.1186","volume":"24","author":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guidong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"issue":"1","key":"8928_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018, Jul, 5;379(1):64\u201373. https:\/\/doi.org\/10.1056\/NEJMra1706169.","journal-title":"N Engl J Med"},{"issue":"5","key":"8928_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"10","key":"8928_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(21)00375-2.","journal-title":"Lancet Oncol"},{"issue":"26","key":"8928_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"6","key":"8928_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"8928_CR6","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.omtm.2024.101250","volume":"32","author":"J Dias","year":"2024","unstructured":"Dias J, Garcia J, Agliardi G, Roddie C. CAR-T cell manufacturing landscape-lessons from the past decade and considerations for early clinical development. Mol Ther Methods Clin Dev. 2024;32(2):101250. https:\/\/doi.org\/10.1016\/j.omtm.2024.101250.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"8928_CR7","doi-asserted-by":"publisher","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024;221(2):e20230903. https:\/\/doi.org\/10.1084\/jem.20230903.","DOI":"10.1084\/jem.20230903"},{"issue":"4","key":"8928_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s44222-023-00031-x","volume":"1","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sperling AS, Smith EL, Mooney DJ. Optimizing the manufacturing and antitumour response of CAR T therapy. Nat Rev Bioeng. 2023;1(4):271\u201385. https:\/\/doi.org\/10.1038\/s44222-023-00031-x.","journal-title":"Nat Rev Bioeng"},{"issue":"10","key":"8928_CR9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290\u201397. https:\/\/doi.org\/10.1038\/nm.2446.","journal-title":"Nat Med"},{"issue":"2","key":"8928_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng. 2022;6(2):118\u201328. https:\/\/doi.org\/10.1038\/s41551-021-00842-6.","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"8928_CR11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s41590-022-01219-w","volume":"23","author":"D Zehn","year":"2022","unstructured":"Zehn D, Thimme R, Lugli E, de Almeida GP, Oxenius A. \u2018Stem-like\u2019 precursors are the fount to sustain persistent CD8+ T cell responses. Nat Immunol. 2022;23(6):836\u201347. https:\/\/doi.org\/10.1038\/s41590-022-01219-w.","journal-title":"Nat Immunol"},{"issue":"3","key":"8928_CR12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41590-025-02388-0","volume":"27","author":"T Hu","year":"2026","unstructured":"Hu T, Zhu Z, Luo Y, Wizzard S, Hoar J, Shinde SS, et al. BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells. Nat Immunol. 2026;27(3):425\u201335. https:\/\/doi.org\/10.1038\/s41590-025-02388-0.","journal-title":"Nat Immunol"},{"issue":"5","key":"8928_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371. https:\/\/doi.org\/10.1038\/s41591-018-0010-1.","journal-title":"Nat Med"},{"issue":"1","key":"8928_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-025-01378-4","volume":"23","author":"Z Chen","year":"2026","unstructured":"Chen Z, Zhu Z, Hu T, Yao C, Wu T. Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy. Cell Mol Immunol. 2026;23(1):1\u201314. https:\/\/doi.org\/10.1038\/s41423-025-01378-4.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"8928_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"8928_CR16","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/j.ymthe.2020.07.023","volume":"28","author":"AC Boroughs","year":"2020","unstructured":"Boroughs AC, Larson RC, Marjanovic ND, Gosik K, Castano AP, Porter CBM, et al. A distinct transcriptional program in human CAR T cells bearing the 4-1BB signaling domain revealed by scRNA-seq. Mol Ther. 2020;28(12):2577\u201392. https:\/\/doi.org\/10.1016\/j.ymthe.2020.07.023.","journal-title":"Mol Ther"},{"issue":"24","key":"8928_CR17","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","volume":"131","author":"AI Salter","year":"2018","unstructured":"Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor\u2013modified T cells: CD19 and the road beyond. Blood. 2018;131(24):2621\u201329. https:\/\/doi.org\/10.1182\/blood-2018-01-785840.","journal-title":"Blood"},{"issue":"1","key":"8928_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","volume":"10","author":"P Wang","year":"2025","unstructured":"Wang P, Wang Y, Zhao X, Zheng R, Zhang Y, Meng R, et al. Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. Signal Transduct Target TherSig Transduct Target Ther. 2025;10(1):20. https:\/\/doi.org\/10.1038\/s41392-024-02096-5.","journal-title":"Signal Transduct Target TherSig Transduct Target Ther"},{"issue":"10","key":"8928_CR19","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.ymthe.2017.07.002","volume":"25","author":"R Tran","year":"2017","unstructured":"Tran R, Myers DR, Denning G, Shields JE, Lytle AM, Alrowais H, et al. Microfluidic transduction harnesses mass transport principles to enhance gene transfer efficiency. Mol Ther. 2017;25(10):2372\u201382. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.002.","journal-title":"Mol Ther"},{"issue":"1","key":"8928_CR20","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1038\/s41598-019-50981-9","volume":"9","author":"N Moore","year":"2019","unstructured":"Moore N, Chevillet JR, Healey LJ, McBrine C, Doty D, Santos J, et al. A microfluidic device to enhance viral transduction efficiency during manufacture of engineered cellular therapies. Sci Rep. 2019;9(1):15101. https:\/\/doi.org\/10.1038\/s41598-019-50981-9.","journal-title":"Sci Rep"},{"issue":"5","key":"8928_CR21","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1039\/D3LC00622K","volume":"24","author":"H Kim","year":"2024","unstructured":"Kim H, Kim S, Lim H, Chung AJ. Expanding CAR-T cell immunotherapy horizons through microfluidics. Lab Chip. 2024;24(5):1088\u2013120. https:\/\/doi.org\/10.1039\/D3LC00622K.","journal-title":"Lab Chip"},{"issue":"1","key":"8928_CR22","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1038\/s41467-025-59789-w","volume":"16","author":"KK Zeming","year":"2025","unstructured":"Zeming KK, Quek KY, Sin WX, Teo DBL, Cheung K-W, Goh CR, et al. Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes. Nat Commun. 2025;16(1):4775. https:\/\/doi.org\/10.1038\/s41467-025-59789-w.","journal-title":"Nat Commun"},{"issue":"5","key":"8928_CR23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1039\/D5LC00492F","volume":"26","author":"JL Duncan","year":"2026","unstructured":"Duncan JL, Arroyo JP, Davalos RV. Microfluidics for cell therapy and manufacturing in oncology and regenerative medicine. Lab Chip. 2026;26(5):1566\u201387. https:\/\/doi.org\/10.1039\/D5LC00492F.","journal-title":"Lab Chip"},{"issue":"22","key":"8928_CR24","doi-asserted-by":"publisher","first-page":"4804","DOI":"10.1039\/D3LC00311F","volume":"23","author":"T Yu","year":"2023","unstructured":"Yu T, Jhita N, Shankles P, Fedanov A, Kramer N, Raikar SS, et al. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow. Lab Chip. 2023;23(22):4804\u201320. https:\/\/doi.org\/10.1039\/D3LC00311F.","journal-title":"Lab Chip"},{"issue":"12","key":"8928_CR25","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1039\/D5LC00139K","volume":"25","author":"V Markelov","year":"2025","unstructured":"Markelov V, Arabuli KV, Gaponenko I, Sergeev V, Shakirova A, Lepik KV, et al. Scalable and ultrafast CAR-T cell production using microfluidics. Lab Chip. 2025;25(12):3005\u201315. https:\/\/doi.org\/10.1039\/D5LC00139K.","journal-title":"Lab Chip"},{"issue":"4","key":"8928_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.tibtech.2024.09.013","volume":"43","author":"S Chen","year":"2025","unstructured":"Chen S, Liu D. Rapid manufacturing of CAR-T therapy: strategies and impact. Trends BiotechnolTrends Biotechnol. 2025;43(4):745\u201348. https:\/\/doi.org\/10.1016\/j.tibtech.2024.09.013.","journal-title":"Trends BiotechnolTrends Biotechnol"},{"issue":"8091","key":"8928_CR27","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41586-025-09539-1","volume":"647","author":"Y Wang","year":"2025","unstructured":"Wang Y, Ma A, Song NJ, Shannon AE, Amankwah YS, Chen X, et al. Proteotoxic stress response drives T cell exhaustion and immune evasion. Nature. 2025;647(8091):1025\u201335. https:\/\/doi.org\/10.1038\/s41586-025-09539-1.","journal-title":"Nature"},{"issue":"1","key":"8928_CR28","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1038\/s41598-025-89070-5","volume":"15","author":"BJ Sytsma","year":"2025","unstructured":"Sytsma BJ, Allain V, Bourke S, Faizee F, Fathi M, Ferreira LMR, et al. Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells. Sci Rep. 2025;15(1):5749. https:\/\/doi.org\/10.1038\/s41598-025-89070-5.","journal-title":"Sci Rep"},{"issue":"9","key":"8928_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019connor RS, Fraietta JA, Patel PR, Scholler J, et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol ResCancer Immunol Res. 2018;6(9):1100\u201309. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0405.","journal-title":"Cancer Immunol ResCancer Immunol Res"},{"issue":"1","key":"8928_CR30","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","volume":"12","author":"M Maschan","year":"2021","unstructured":"Maschan M, Caimi PF, Reese-Koc J, Sanchez GP, Sharma AA, Molostova O, et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 2021;12(1):7200. https:\/\/doi.org\/10.1038\/s41467-021-27312-6.","journal-title":"Nat Commun"},{"issue":"7","key":"8928_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer JBlood Cancer J. 2022;12(7):104. https:\/\/doi.org\/10.1038\/s41408-022-00694-6.","journal-title":"Blood Cancer JBlood Cancer J"},{"issue":"7926","key":"8928_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609(7926):369\u201374. https:\/\/doi.org\/10.1038\/s41586-022-05140-y.","journal-title":"Nature"},{"key":"8928_CR33","doi-asserted-by":"publisher","unstructured":"Agliardi G, Dias J, Rampotas A, Garcia J, Roddie C. Accelerating and optimising CAR T-cell manufacture to deliver better patient products. Lancet HaematolThe Lancet Haematol. 2025;12(1):e57\u201367. https:\/\/doi.org\/10.1016\/S2352-3026(24)00273-4.","DOI":"10.1016\/S2352-3026(24)00273-4"},{"issue":"6","key":"8928_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/CU9.0000000000000305","volume":"19","author":"H Tang","year":"2025","unstructured":"Tang H, Guo L, Zhang W, Tang D. Chimeric antigen receptor\u2013based cell therapy for treating urological tumors. Curr Urol. 2025;19(6):363\u201375. https:\/\/doi.org\/10.1097\/CU9.0000000000000305.","journal-title":"Curr Urol"},{"key":"8928_CR35","doi-asserted-by":"publisher","first-page":"1175570","DOI":"10.3389\/fbioe.2023.1175570","volume":"11","author":"RE Waugh","year":"2023","unstructured":"Waugh RE, Lomakina E, Amitrano A, Kim M. Activation effects on the physical characteristics of T lymphocytes. Front Bioeng BiotechnolFront. Bioeng. Biotechnol. 2023;11:1175570. https:\/\/doi.org\/10.3389\/fbioe.2023.1175570.","journal-title":"Front Bioeng BiotechnolFront. Bioeng. Biotechnol"},{"issue":"9","key":"8928_CR36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41423-025-01321-7","volume":"22","author":"D Zou","year":"2025","unstructured":"Zou D, Li XC, Chen W. Beyond T-cell subsets: stemness and adaptation redefining immunity and immunotherapy. Cell Mol Immunol. 2025;22(9):957\u201374. https:\/\/doi.org\/10.1038\/s41423-025-01321-7.","journal-title":"Cell Mol Immunol"},{"key":"8928_CR37","doi-asserted-by":"publisher","unstructured":"Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, Bezzecchi E. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022;132(12):e150807. https:\/\/doi.org\/10.1172\/JCI150807.","DOI":"10.1172\/JCI150807"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08928-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:50:36Z","timestamp":1790081436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8928"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08928-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Second Qilu Hospital of Shandong University (Approval No. KYLL202512825), and the same ethics approval covered both healthy-donor blood collection and the animal experiments. Written informed consent was obtained from all healthy donors before peripheral blood collection, and all human samples were de-identified before processing. The animal experiments were conducted in accordance with institutional guidelines for the care and use of laboratory animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1207"}}